Last $4.70 USD
Change Today -0.16 / -3.29%
Volume 87.5K
CCXI On Other Exchanges
As of 8:10 PM 11/21/14 All times are local (Market data is delayed by at least 15 minutes).

chemocentryx inc (CCXI) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/20/14 - $8.25
52 Week Low
10/2/14 - $4.09
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for CHEMOCENTRYX INC (CCXI)

Related News

No related news articles were found.

chemocentryx inc (CCXI) Related Businessweek News

No Related Businessweek News Found

chemocentryx inc (CCXI) Details

ChemoCentryx, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders, and cancer in the United States. Its drug candidates under clinical stage include Vercirnon, which is in Phase III clinical trial for the treatment of patients with moderate-to-severe Crohn’s disease; CCX140 that is in Phase II clinical trial for the treatment of patients with diabetic nephropathy, a form of kidney disease; and CCX354 that completed a Phase II proof-of-concept clinical trial for the treatment of rheumatoid arthritis. The company’s drug candidates also comprise CCX168, which is in a Phase II clinical trial for the treatment of anti-neutrophil cytoplasmic antibody associated renal vasculitis; CCX872 that is under Phase I clinical development targeting CCR2 for expanded indications of renal disease; and CCX507, a de novo wholly-owned CCR9 inhibitor, which is in Phase I clinical trials for inflammatory bowel disease and related disorders. Its preclinical stage programs comprise CCX650, an orally active drug for the treatment of glioblastoma multiforme; CCR4 inhibitor for atopic dermatitis; CCX6239, an orally administered CCR4 antagonist with potential utility in the treatment of atopic dermatitis; CCR6 inhibitor for autoimmune diseases; and CXCR6 inhibitor for liver diseases. The company was founded in 1997 and is headquartered in Mountain View, California.

60 Employees
Last Reported Date: 03/14/14
Founded in 1997

chemocentryx inc (CCXI) Top Compensated Officers

Founder, Chairman, Chief Executive Officer an...
Total Annual Compensation: $510.0K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $372.2K
Chief Medical Officer
Total Annual Compensation: $369.4K
Chief Business Officer and Treasurer
Total Annual Compensation: $354.5K
Compensation as of Fiscal Year 2013.

chemocentryx inc (CCXI) Key Developments

ChemoCentryx, Inc. Reports Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014; Provides an Update on Corporate and Clinical Development Activities

ChemoCentryx, Inc. reported consolidated earnings results for the third quarter and nine months ended September 30, 2014. For the quarter, loss from operations was $11.1 million against $9.6 million last year. Net loss was $10.9 million or $0.25 per basic and diluted share for the third quarter of 2014 compared to $9.4 million or $0.22 per basic and diluted share in same period in 2013. For the nine months, loss from operations was $35.1 million against $29.4 million last year. Net loss was $34.7 million or $0.80 per basic and diluted share compared to $29.1 million or $0.72 per basic and diluted share in same period in 2013. The company provided an update on the company's corporate and clinical development activities. C5aR Program - CCX168 targets the chemoattractant receptor known as C5aR (which binds the complement fragment C5a). The company has successfully completed and reported positive clinical data with CCX168 from the first two steps of a three-step Phase II clinical trial, named the CLEAR trial, in patients with anti-neutrophil cytoplasmic antibody, or ANCA, associated vasculitis, or AAV, a disease which can lead to renal and pulmonary failure. C5aR is also believed to play a role in other renal disease settings such as IgA nephropathy, atypical hemolytic uremic syndrome (aHUS), and lupus nephritis. The company commenced clinical site initiations for a second Phase II clinical trial with CCX168 in North America in patients with AAV. CCR9 Program - CCX507 targets the chemokine receptor known as CCR9 and is a second-generation CCR9 inhibitor for the treatment of inflammatory bowel disease, or IBD. Vercirnon is a Phase III-ready drug candidate for the treatment of patients with moderate-to-severe Crohn's disease. The company presented Phase I clinical data demonstrating that CCX507 is safe and well tolerated in healthy volunteers, and effectively blocked CCR9 on circulating leukocytes. Preclinical data were also presented showing that CCX507, in combination with an anti-alpha4beta7 (47) blocking antibody reduced the severity of colitis more effectively in vivo than monotherapy treatment with either CCX507 or the anti-ALPHA>47 blocking antibody alone (American College of Gastroenterology (ACG) Annual Meeting). The company presented Phase III SHIELD 4 data which demonstrated that patients experienced improved response and remission rates when taking a higher dose of vercirnon. Additionally, identified response and remission rate similarities in SHIELD 4 and PROTECT-1 with higher doses of vercirnon in patients who completed SHIELD 4 prior to the premature study termination (ACG Annual Meeting).

ChemoCentryx, Inc. to Report Q3, 2014 Results on Nov 05, 2014

ChemoCentryx, Inc. announced that they will report Q3, 2014 results at 5:00 PM, US Eastern Standard Time on Nov 05, 2014

ChemoCentryx, Inc., Q3 2014 Earnings Call, Nov 05, 2014

ChemoCentryx, Inc., Q3 2014 Earnings Call, Nov 05, 2014


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CCXI:US $4.70 USD -0.16

CCXI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Biogen Idec Inc $303.55 USD +4.45
Bristol-Myers Squibb Co $58.80 USD +0.19
Incyte Corp $72.27 USD +0.66
Takeda Pharmaceutical Co Ltd ¥4,974 JPY +7.50
Teva Pharmaceutical Industries Ltd $57.40 USD +0.68
View Industry Companies

Industry Analysis


Industry Average

Valuation CCXI Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 280.9x
Price/Book 1.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales 163.3x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CHEMOCENTRYX INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at